| |  Online-Ressource |
|---|
| Verfasst von: | Dent, Rebecca [VerfasserIn]  |
|---|
| | André, F. [VerfasserIn] |
|---|
| | Gonçalves, A. [VerfasserIn] |
|---|
| | Martin, M. [VerfasserIn] |
|---|
| | Schmid, P. [VerfasserIn] |
|---|
| | Schütz, Florian [VerfasserIn] |
|---|
| | Kümmel, S. [VerfasserIn] |
|---|
| | Swain, S. M. [VerfasserIn] |
|---|
| | Bilici, A. [VerfasserIn] |
|---|
| | Loirat, D. [VerfasserIn] |
|---|
| | Villalobos Valencia, R. [VerfasserIn] |
|---|
| | Im, S. -A. [VerfasserIn] |
|---|
| | Park, Y. H. [VerfasserIn] |
|---|
| | De Laurentis, M. [VerfasserIn] |
|---|
| | Colleoni, M. [VerfasserIn] |
|---|
| | Guarneri, V. [VerfasserIn] |
|---|
| | Bianchini, G. [VerfasserIn] |
|---|
| | Li, H. [VerfasserIn] |
|---|
| | Kirchmayer Machackova, Z. [VerfasserIn] |
|---|
| | Mouta, J. [VerfasserIn] |
|---|
| | Deurloo, R. [VerfasserIn] |
|---|
| | Gan, X. [VerfasserIn] |
|---|
| | Fan, M. [VerfasserIn] |
|---|
| | Mani, A. [VerfasserIn] |
|---|
| | Swat, A. [VerfasserIn] |
|---|
| | Cortés, J. [VerfasserIn] |
|---|
| Titel: | IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer |
|---|
| Verf.angabe: | R. Dent, F. André, A. Gonçalves, M. Martin, P. Schmid, F. Schütz, S. Kümmel, S.M. Swain, A. Bilici, D. Loirat, R. Villalobos Valencia, S.-A. Im, Y.H. Park, M. De Laurentis, M. Colleoni, V. Guarneri, G. Bianchini, H. Li, Z. Kirchmayer Machackova, J. Mouta, R. Deurloo, X. Gan, M. Fan, A. Mani, A. Swat & J. Cortés |
|---|
| E-Jahr: | 2024 |
|---|
| Jahr: | July 2024 |
|---|
| Umfang: | 13 S. |
|---|
| Illustrationen: | Illustrationen |
|---|
| Fussnoten: | Online verfügbar: 15. Mai 2024, Artikelversion: 21. Juni 2024 ; Gesehen am 12.11.2024 |
|---|
| Titel Quelle: | Enthalten in: Annals of oncology |
|---|
| Ort Quelle: | Amsterdam [u.a.] : Elsevier, 1990 |
|---|
| Jahr Quelle: | 2024 |
|---|
| Band/Heft Quelle: | 35(2024), 7 vom: Juli, Seite 630-642 |
|---|
| ISSN Quelle: | 1569-8041 |
|---|
| Abstract: | Background - Immune checkpoint inhibitors improve the efficacy of first-line chemotherapy for patients with programmed death-ligand 1 (PD-L1)-positive unresectable locally advanced/metastatic triple-negative breast cancer (aTNBC), but randomised data in rapidly relapsing aTNBC are scarce. - Patients and methods - IMpassion132 (NCT03371017) enrolled patients with aTNBC relapsing <12 months after last chemotherapy dose (anthracycline and taxane required) or surgery for early TNBC. PD-L1 status was centrally assessed using SP142 before randomisation. Initially patients were enrolled irrespective of PD-L1 status. From August 2019, enrolment was restricted to PD-L1-positive (tumour immune cell ≥1%) aTNBC. Patients were randomised 1:1 to placebo or atezolizumab 1200 mg every 21 days with investigator-selected chemotherapy until disease progression or unacceptable toxicity. Stratification factors were chemotherapy regimen (carboplatin plus gemcitabine or capecitabine monotherapy), visceral (lung and/or liver) metastases and (initially) PD-L1 status. The primary endpoint was overall survival (OS), tested hierarchically in patients with PD-L1-positive tumours and then, if positive, in the modified intent-to-treat (mITT) population (all-comer patients randomised pre-August 2019). Secondary endpoints included progression-free survival (PFS), objective response rate (ORR) and safety. - Results - Among 354 patients with rapidly relapsing PD-L1-positive aTNBC, 68% had a disease-free interval of <6 months and 73% received carboplatin/gemcitabine. The OS hazard ratio was 0.93 (95% confidence interval 0.73-1.20, P = 0.59; median 11.2 months with placebo versus 12.1 months with atezolizumab). mITT and subgroup results were consistent. Median PFS was 4 months across treatment arms and populations. ORRs were 28% with placebo versus 40% with atezolizumab. Adverse events (predominantly haematological) were similar between arms and as expected with atezolizumab plus carboplatin/gemcitabine or capecitabine following recent chemotherapy exposure. - Conclusions - OS, which is dismal in patients with TNBC relapsing within <12 months, was not improved by adding atezolizumab to chemotherapy. A biology-based definition of intrinsic resistance to immunotherapy in aTNBC is urgently needed to develop novel therapies for these patients in next-generation clinical trials. |
|---|
| DOI: | doi:10.1016/j.annonc.2024.04.001 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
kostenfrei: Volltext: https://doi.org/10.1016/j.annonc.2024.04.001 |
|---|
| | kostenfrei: Volltext: https://www.sciencedirect.com/science/article/pii/S0923753424001078 |
|---|
| | DOI: https://doi.org/10.1016/j.annonc.2024.04.001 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | disease-free interval |
|---|
| | immune checkpoint |
|---|
| | PD-L1 |
|---|
| | prognosis |
|---|
| | rapid relapse |
|---|
| | triple-negative breast cancer |
|---|
| K10plus-PPN: | 1908294779 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer / Dent, Rebecca [VerfasserIn]; July 2024 (Online-Ressource)
